Ilsung Sitamet Tablet 50/500 mg
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Prescription medication · Combination
Ilsung IS Co., Ltd.
MFDS item code 201503332 · Approved 2015.05.29
This product's status changed to Expired on 2025.05.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to assist patients with type 2 diabetes in controlling their blood sugar levels by taking sitagliptin and metformin together. It is more effective when combined with dietary and exercise therapy and contributes to the stable management of blood sugar levels. This helps reduce the risk of complications and aids in maintaining a healthy lifestyle.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy in whom adequate glycemic control cannot be achieved with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is one tablet of 50/500 mg twice daily. The dose may be increased to one tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the current metformin dose. - Patients switching to this medicine from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should take the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in treatment for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other condition that may increase the risk of lactic acidosis, with the following dosage adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with impaired hepatic function because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medicine).
This drug contains both sitagliptin and metformin and is used for blood sugar control in patients with type 2 diabetes. While taking this drug, serious allergic reactions may occur, so if symptoms such as rash, difficulty breathing, or swelling of the face or neck appear, discontinue use immediately and consult a healthcare professional. Additionally, this drug can cause inflammation of the pancreas, known as pancreatitis, so if symptoms such as abdominal pain, nausea, vomiting, or fever occur, notify a healthcare professional immediately. Patients with severely impaired kidney function, heart failure, acute myocardial infarction, or severe infection should not take this drug. Temporarily discontinue this drug before tests using contrast agents and resume after confirming that kidney function is normal. It is safer not to take this drug during pregnancy or in women who may become pregnant, and while breastfeeding. There is a rare but serious side effect called lactic acidosis that can occur during the use of this drug. If symptoms such as muscle pain, weakness, difficulty breathing, or abdominal pain arise, inform a physician immediately. Also, this drug poses a risk of hypoglycemia, so caution is advised when skipping meals or engaging in vigorous exercise, and special attention should be paid to symptoms of hypoglycemia when used in conjunction with other hypoglycemic agents. This drug is not recommended for patients with impaired liver function or severe liver disease. Regular checks of kidney function and blood tests should be conducted during use, as vitamin B12 deficiency may occur, and supplementation may be necessary if needed. There are other drugs that may interact with this medication, so all medications currently being taken should be disclosed to healthcare professionals for careful management. If surgery is planned, this drug should be discontinued 48 hours before surgery, and resumed only after confirming normal kidney function post-surgery. Elderly patients are likely to have reduced kidney function, necessitating dosage adjustments and regular kidney function tests. It is advisable to avoid alcohol intake during treatment, and to consult healthcare professionals in case of sudden dehydration, severe diarrhea, or vomiting.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air ingress, and ideally kept at room temperature between 1 and 30 degrees Celsius. This storage method helps maintain the drug's efficacy for a longer period.
Bright pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP x 3 pieces)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Prescription medication · Combination
Ilsung IS Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.